Editorial
Exciting changes

IT HAS BEEN a hectic year, but the transition is complete. After four years of serving as Managing Editor of the *Journal of Commercial Biotechnology* under the auspices of Palgrave-MacMillan, I have acquired the journal and have incorporated it into thinkBiotech along with my portfolio of books and websites on the business of biotechnology. I would like to personally and publicly thank Neil Henderson at Palgrave-MacMillan for his training and support, and for his assistance throughout the transition process.

With ownership and editorial control I have implemented many changes, and look forward to bringing even more. An exciting line up of special issues, coming out over the next two years, is also in the works.

The first change you may have noticed is the new cover and full-color interior layout of the JCB, but the changes go much deeper than that. I have recruited three associate editors to share the editorial load as I take on more of the publishing responsibilities. They will also be soliciting papers in their areas of expertise, improve the breadth and quality of submissions and published papers.

A new section, *From the Boardroom*, has been added, complementing the *From the Classroom* and *Legal/Regulatory Update* sections in providing practical actionable guidance alongside the *Original Articles*.

The JCB website also has new social functionality — a Twitter stream (@jcommbiotech) and connectivity with LinkedIn and Facebook. Each paper also has an *Add Comment* function, enabling feedback and discussion. The LinkedIn group at http://www.linkedin.com/groups?gid=1241807 is also a great resource to continue the dialogue between JCB issues.

I look forward to continuing to develop the *Journal of Commercial Biotechnology* as an un-matched resource on biotechnology commercialization. I look forward to your thoughts on the new design and ideas for future issues at editor@CommercialBiotechnology.com.

Yali Friedman
Chief Editor and Publisher